Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The significance of the fusion partner gene genomic neighborhood analysis in translocation-defined tumors

E. Mosaieby, P. Martínek, O. Ondič

. 2022 ; 10 (8) : e1994. [pub] 20220527

Language English Country United States

Document type Journal Article

INTRODUCTION: This study presents a novel molecular parameter potentially co-defining tumor biology-the total tumor suppressor gene (TSG) count at chromosomal loci harboring genes rearranged in fusion-defined tumors. It belongs to the family of molecular parameters created using a black-box approach. METHOD: It is based on a public curated Texas TSG database. Its data are regrouped based on individual genes loci using another public database (Genecards). The total TSG count for NTRK (NTRK1; OMIM: 191315; NTRK2; OMIM: 600456; NTRK3; OMIM: 191316), NRG1 (OMIM: 142445), and RET (OMIM: 164761) rearranged tumors in patients treated with a theranostic approach is calculated using the results of recently published studies. RESULTS: Altogether 138 loci containing at least three TSGs are identified. These include 21 "extremely hot" spots, with 10 to 28 TSGs mapping to a given locus. However, the study falls short of finding a correlation between tumor regression or patient survival and the TSG count owing to a low number of cases meeting the study criteria. CONCLUSION: The total TSG count alone cannot predict the biology of translocation-defined tumors. The addition of other parameters, including microsatellite instability (MSI), tumor mutation burden (TMB), homologous recombination repair deficiency (HRD), and copy number heterogeneity (CNH), might be helpful. Thus a multi-modal data integration is advocated. We believe that large scale studies should evaluate the significance and value of the total TSG count.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025087
003      
CZ-PrNML
005      
20221031101256.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/mgg3.1994 $2 doi
035    __
$a (PubMed)35621010
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mosaieby, Elaheh $u Molecular Genetics Department, Bioptická Laboratoř s.r.o., Pilsen, Czech Republic $u Department of Pathology, Medical Faculty in Pilsen, Charles University, Prague, Czech Republic
245    14
$a The significance of the fusion partner gene genomic neighborhood analysis in translocation-defined tumors / $c E. Mosaieby, P. Martínek, O. Ondič
520    9_
$a INTRODUCTION: This study presents a novel molecular parameter potentially co-defining tumor biology-the total tumor suppressor gene (TSG) count at chromosomal loci harboring genes rearranged in fusion-defined tumors. It belongs to the family of molecular parameters created using a black-box approach. METHOD: It is based on a public curated Texas TSG database. Its data are regrouped based on individual genes loci using another public database (Genecards). The total TSG count for NTRK (NTRK1; OMIM: 191315; NTRK2; OMIM: 600456; NTRK3; OMIM: 191316), NRG1 (OMIM: 142445), and RET (OMIM: 164761) rearranged tumors in patients treated with a theranostic approach is calculated using the results of recently published studies. RESULTS: Altogether 138 loci containing at least three TSGs are identified. These include 21 "extremely hot" spots, with 10 to 28 TSGs mapping to a given locus. However, the study falls short of finding a correlation between tumor regression or patient survival and the TSG count owing to a low number of cases meeting the study criteria. CONCLUSION: The total TSG count alone cannot predict the biology of translocation-defined tumors. The addition of other parameters, including microsatellite instability (MSI), tumor mutation burden (TMB), homologous recombination repair deficiency (HRD), and copy number heterogeneity (CNH), might be helpful. Thus a multi-modal data integration is advocated. We believe that large scale studies should evaluate the significance and value of the total TSG count.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a fúze genů $7 D050939
650    _2
$a genomika $7 D023281
650    _2
$a lidé $7 D006801
650    _2
$a mutace $7 D009154
650    12
$a nádory $x genetika $x patologie $7 D009369
650    _2
$a translokace genetická $7 D014178
655    _2
$a časopisecké články $7 D016428
700    1_
$a Martínek, Petr $u Molecular Genetics Department, Bioptická Laboratoř s.r.o., Pilsen, Czech Republic
700    1_
$a Ondič, Ondrej $u Molecular Genetics Department, Bioptická Laboratoř s.r.o., Pilsen, Czech Republic $u Department of Pathology, Medical Faculty in Pilsen, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000240385641
773    0_
$w MED00205675 $t Molecular genetics & genomic medicine $x 2324-9269 $g Roč. 10, č. 8 (2022), s. e1994
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35621010 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031101254 $b ABA008
999    __
$a ok $b bmc $g 1854677 $s 1176377
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 10 $c 8 $d e1994 $e 20220527 $i 2324-9269 $m Molecular genetics & genomic medicine $n Mol Genet Genomic Med $x MED00205675
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...